US6117641A
(en)
|
1996-04-11 |
2000-09-12 |
Mitotix, Inc. |
Assays and reagents for identifying anti-fungal agents and uses related thereto
|
US6727082B1
(en)
|
1996-04-11 |
2004-04-27 |
Gpc Biotech Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
JP2001513622A
(ja)
|
1996-04-11 |
2001-09-04 |
マイトティックス インコーポレーテッド |
抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用
|
EP0918771A4
(de)
*
|
1996-07-15 |
2001-02-07 |
Bristol Myers Squibb Co |
Thiadioxobenzodiazepin-inhibitoren der farnesyl-protein-transferase
|
JP2001514191A
(ja)
*
|
1997-08-27 |
2001-09-11 |
メルク エンド カムパニー インコーポレーテッド |
癌の治療方法
|
JP2001519387A
(ja)
*
|
1997-09-29 |
2001-10-23 |
ブリストル−マイヤーズ スクイブ カンパニー |
ファルネシルたんぱく転移酵素のインヒビター
|
US6458783B1
(en)
*
|
1997-09-29 |
2002-10-01 |
Bristol-Myers Squibb Company |
Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
|
CN1213022C
(zh)
*
|
1997-12-22 |
2005-08-03 |
拜尔有限公司 |
用对称和不对称的取代二苯脲抑制raf激酶
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
US6423519B1
(en)
|
1998-07-15 |
2002-07-23 |
Gpc Biotech Inc. |
Compositions and methods for inhibiting fungal growth
|
WO2000034437A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6316436B1
(en)
|
1998-12-08 |
2001-11-13 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
TR200102109T2
(tr)
*
|
1999-01-21 |
2001-12-21 |
Bristol-Myers Squibb Company |
Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod.
|
CA2363169A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
MXPA01010292A
(es)
|
1999-04-15 |
2002-10-23 |
Squibb Bristol Myers Co |
Inhibidores ciclicos de la proteina tirosina cinasa.
|
US20060025388A1
(en)
|
1999-04-30 |
2006-02-02 |
Glick Gary D |
Compositions and methods relating to novel compounds and targets thereof
|
US20020115696A1
(en)
|
1999-06-18 |
2002-08-22 |
Yoel Kloog |
Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
|
CA2377254C
(en)
*
|
1999-06-18 |
2009-08-18 |
Thyreos Corporation |
Non-malignant disease treatment with ras antagonists
|
WO2001002342A1
(en)
|
1999-06-30 |
2001-01-11 |
Igt Pharma Inc. |
2-aminoindane analogs
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
EP1088821A1
(de)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmazeutisch wirksamer Sulfonamid Derivate
|
US6100395A
(en)
*
|
2000-01-10 |
2000-08-08 |
Bristol-Myers Squibb Company |
Reductive alkylation of secondary amines with hydrosilane
|
DE60130976T2
(de)
|
2000-02-24 |
2008-07-17 |
Janssen Pharmaceutica N.V. |
Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
EP1283055A4
(de)
*
|
2000-04-07 |
2003-05-07 |
Takeda Chemical Industries Ltd |
Lösliche promotoren der sekretion von beta amyloid protein vorläufer
|
ATE434615T1
(de)
*
|
2000-11-21 |
2009-07-15 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
US20040044032A1
(en)
*
|
2000-11-28 |
2004-03-04 |
End David William |
Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease
|
WO2002051835A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
DE60119383T2
(de)
*
|
2000-12-27 |
2007-04-19 |
Janssen Pharmaceutica N.V. |
Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
|
US6645966B2
(en)
|
2001-01-22 |
2003-11-11 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
SK288098B6
(sk)
|
2001-01-25 |
2013-07-02 |
Bristol-Myers Squibb Company |
Methods of administering epothilone analogs for the treatment of cancer
|
JP4366081B2
(ja)
|
2001-05-22 |
2009-11-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
高度に精製されたアンチエンドトキシン化合物
|
EP1288713A1
(de)
*
|
2001-08-29 |
2003-03-05 |
Chugai Photo Chemical Co. Ltd. |
Verarbeitungsagens für lichtempfindliches silberhalogenidhaltiges Farbfotomaterial und Verfahren zu dessen Verarbeitung
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
EP1443936A4
(de)
*
|
2001-11-13 |
2006-01-11 |
Bristol Myers Squibb Co |
Verfahren zur herstellung von 3,7-disubstituierten-2,3,4,5- tetrahydro-1h-1,4-benzodiazepin-verbindungen
|
AU2003209116A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
WO2003068746A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas as kinase inhibitors
|
AU2003214110A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Ciba Specialty Chemicals Holding Inc. |
4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
JP2006511445A
(ja)
*
|
2002-06-07 |
2006-04-06 |
コーティカル・ピーティーワイ・リミテッド |
マクロファージ遊走阻止因子(mif)のサイトカインまたは生物学的活性を阻害するナフタレン誘導体
|
WO2003106628A2
(en)
*
|
2002-06-17 |
2003-12-24 |
Bristol-Myers Squibb Company |
Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
|
EP1534862A4
(de)
*
|
2002-08-07 |
2007-10-10 |
Exelixis Inc |
Modulatoren von rabggt und verfahren zu deren verwendung
|
US7632858B2
(en)
*
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
WO2004067008A1
(ja)
*
|
2003-01-28 |
2004-08-12 |
Takeda Pharmaceutical Company Limited |
受容体作動薬
|
JP2004346059A
(ja)
*
|
2003-01-28 |
2004-12-09 |
Takeda Chem Ind Ltd |
受容体作動薬
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
PT1636585E
(pt)
|
2003-05-20 |
2008-03-27 |
Bayer Pharmaceuticals Corp |
Diarilureias com actividade inibidora de cinase
|
JP4777887B2
(ja)
|
2003-07-23 |
2011-09-21 |
バイエル、ファーマシューテイカルズ、コーポレイション |
病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
|
US7417026B2
(en)
|
2003-08-13 |
2008-08-26 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
JP2007535479A
(ja)
|
2003-08-13 |
2007-12-06 |
チルドレンズ ホスピタル メディカル センター |
GTPaseを調節するためのキメラペプチド
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
US7517890B2
(en)
|
2003-11-20 |
2009-04-14 |
Children's Hospital Medical Center |
GTPase inhibitors and methods of use
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
CA2559282A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
US20060106060A1
(en)
*
|
2004-03-18 |
2006-05-18 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
EP1744751A4
(de)
*
|
2004-03-18 |
2010-03-10 |
Brigham & Womens Hospital |
Verfahren zur behandlung von synucleinopathien
|
US7323455B2
(en)
*
|
2004-03-24 |
2008-01-29 |
Wyeth |
7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
|
US20050272723A1
(en)
*
|
2004-04-27 |
2005-12-08 |
The Regents Of The University Of Michigan |
Methods and compositions for treating diseases and conditions associated with mitochondrial function
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
PL2362218T3
(pl)
*
|
2004-11-05 |
2015-02-27 |
Janssen Pharmaceutica Nv |
Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej
|
PT1817013E
(pt)
|
2004-11-18 |
2008-08-07 |
Brystol Myers Squibb Company |
Pérola com revestimento entérico compreendendo ixabepilona
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
EP1867639A1
(de)
*
|
2005-03-25 |
2007-12-19 |
Kissei Pharmaceutical Co., Ltd. |
Harnstoffderivat, dieses enthaltende medizinische zusammensetzung und ihre medizinische verwendung
|
US20060235006A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
EP1879881A2
(de)
*
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibitoren der 11-beta-hydroxysteroiddehydrogenase vom typ i
|
DE602006021312D1
(de)
*
|
2005-06-09 |
2011-05-26 |
Bristol Myers Squibb Co |
Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
CA2617056A1
(en)
|
2005-07-29 |
2007-02-08 |
Children's Hospital Medical Center |
Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
|
US7700592B2
(en)
|
2005-08-25 |
2010-04-20 |
Schering Corporation |
α2C adrenoreceptor agonists
|
WO2007024949A2
(en)
|
2005-08-25 |
2007-03-01 |
Schering Corporation |
Alpha2c adrenoreceptor agonists
|
WO2007035425A2
(en)
|
2005-09-16 |
2007-03-29 |
Janssen Pharmaceutica N.V. |
Cyclopropyl amines as modulators of the histamine h3 receptor
|
US20090099197A1
(en)
*
|
2005-11-15 |
2009-04-16 |
Bristol-Myers Squibb Company |
Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
|
CA2652648C
(en)
*
|
2006-02-14 |
2016-10-25 |
Vertex Pharmaceuticals Incorporated |
Dihydrodiazepines useful as inhibitors of protein kinases
|
RU2475483C2
(ru)
|
2006-04-20 |
2013-02-20 |
Янссен Фармацевтика Н.В. |
Ингибиторы с-fms киназы
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
WO2007124316A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
CN101600728A
(zh)
|
2006-12-04 |
2009-12-09 |
伊利诺斯大学理事会 |
使用铜氧还蛋白和富含CpG的DNA治疗癌症的组合物和方法
|
EA200970583A1
(ru)
|
2006-12-14 |
2009-12-30 |
Янссен Фармацевтика Н.В. |
Способ получения пиперазиниловых и диазепаниловых производных бензамида
|
WO2008089135A2
(en)
*
|
2007-01-12 |
2008-07-24 |
University Of South Florida |
Identification of biomarkers predictive of dasatinib effects in cancer cells
|
BRPI0806451A2
(pt)
|
2007-02-08 |
2014-07-15 |
Univ Illinois |
Composições e métodos para a prevenção do câncer com cupredoxinas
|
WO2008141081A1
(en)
*
|
2007-05-10 |
2008-11-20 |
Amr Technology, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2008144981A1
(fr)
|
2007-05-25 |
2008-12-04 |
Topharman Shanghai Co., Ltd. |
Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
|
EP2155722B1
(de)
|
2007-06-05 |
2013-08-14 |
Merck Sharp & Dohme Corp. |
Polycyclische indazolderivate und deren verwendung als erk-inhibitoren zur behandlung von krebs
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
WO2009105140A2
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
JP5785491B2
(ja)
*
|
2008-05-05 |
2015-09-30 |
サノフイ |
アシルアミノ置換縮合シクロペンタンカルボン酸誘導体及び医薬としてのその使用
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
BRPI0920927A2
(pt)
*
|
2008-11-13 |
2019-09-24 |
Link Medicine Corp |
derivados de azaquinolinona e usos dos mesmos
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
CA2763008A1
(en)
*
|
2009-05-26 |
2010-12-02 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
AU2010256360A1
(en)
|
2009-06-05 |
2012-01-12 |
Astrazeneca Ab |
Aminopyrrolidinone derivatives and uses thereof
|
HUE033312T2
(en)
|
2009-07-20 |
2017-11-28 |
Bristol Myers Squibb Co |
Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases
|
EP2483263B1
(de)
|
2009-09-30 |
2018-07-18 |
Merck Sharp & Dohme Corp. |
Heterocyclische verbindungen als erk-hemmer
|
CA2915237C
(en)
|
2009-11-17 |
2017-10-10 |
The Regents Of The University Of Michigan |
1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
|
EP2557078B1
(de)
|
2010-04-06 |
2016-03-23 |
Nippon Soda Co., Ltd. |
Stickstoffhaltige heterozyklische verbindung und herstellungsverfahren dafür
|
AU2014201036B2
(en)
*
|
2010-04-06 |
2015-07-16 |
Nippon Soda Co., Ltd |
Nitrogen-containing heterocyclic compound and method for producing same
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
BR112013018534B1
(pt)
|
2011-01-20 |
2021-04-06 |
Board Of Regents, The University Of Texas System |
Agente de contraste, seus métodos de preparação, e produto de combinação
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
KR102073445B1
(ko)
|
2012-07-31 |
2020-02-04 |
다우 글로벌 테크놀로지스 엘엘씨 |
올레핀 중합 촉매 활성화제의 제조 방법
|
IN2015DN00659A
(de)
|
2012-08-07 |
2015-06-26 |
Janssen Pharmaceutica Nv |
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
CN104768962B
(zh)
|
2012-11-17 |
2017-04-05 |
北京市丰硕维康技术开发有限责任公司 |
离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
|
TW201524952A
(zh)
*
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Kras g12c之共價抑制劑
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
CN107075469A
(zh)
|
2014-06-27 |
2017-08-18 |
加利福尼亚大学董事会 |
培养的哺乳动物角膜缘干细胞、其产生方法和其用途
|
EP3280708B1
(de)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituierte chinazolin verbindungen und verfahren zu deren verwendung
|
MX2017013275A
(es)
|
2015-04-15 |
2018-01-26 |
Araxes Pharma Llc |
Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
SG10202101740QA
(en)
|
2015-08-17 |
2021-04-29 |
Kura Oncology Inc |
Methods of treating cancer patients with farnesyl transferase inhibitors
|
EP3356359B1
(de)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
JP7160688B2
(ja)
*
|
2016-05-24 |
2022-10-25 |
ジェネンテック, インコーポレイテッド |
Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
JP2019534290A
(ja)
|
2016-11-03 |
2019-11-28 |
クラ オンコロジー, インコーポレイテッド |
癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
|
EP3573967A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Kondensierte bicyclische hetero-hetero-verbindungen und verfahren zur verwendung davon
|
EP3573970A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalin-1-yl)chinazolin-2-yl)azetidin-1-yl)prop-2-en-1-on-derivate und ähnliche verbindungen wie kras g12c-inhibitoren zur behandlung von krebs
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3432883B1
(de)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
|
BR112019024674A2
(pt)
|
2017-05-25 |
2020-06-16 |
Araxes Pharma Llc |
Inibidores covalentes da kras
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3681885B1
(de)
|
2017-09-15 |
2024-02-28 |
Forma Therapeutics, Inc. |
Tetrahydroimidazo-chinolin-zusammensetzungen als cbp/p300-inhibitoren
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
MX2023013508A
(es)
|
2018-06-29 |
2023-12-13 |
Forma Therapeutics Inc |
Inhibicion de la proteina de union a creb (cbp).
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
SG11202106599WA
(en)
|
2018-12-21 |
2021-07-29 |
Kura Oncology Inc |
Therapies for squamous cell carcinomas
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
EP3972978A4
(de)
*
|
2019-05-20 |
2023-04-26 |
California Institute Of Technology |
Kras-g12c-inhibitoren und ihre verwendungen
|
JP2023522784A
(ja)
|
2020-04-27 |
2023-05-31 |
ノバルティス アーゲー |
眼細胞療法のための方法及び組成物
|
US11795168B2
(en)
|
2020-09-23 |
2023-10-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
|
US11801243B2
(en)
|
2020-09-23 |
2023-10-31 |
Forma Therapeutics, Inc. |
Bromodomain inhibitors for androgen receptor-driven cancers
|
CN115745960A
(zh)
*
|
2021-09-02 |
2023-03-07 |
中国科学院上海药物研究所 |
一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
|
CN114230529A
(zh)
*
|
2021-11-03 |
2022-03-25 |
河南大学 |
四氢喹喔啉磺酰胺衍生物及其制备方法与用途
|
WO2023143389A1
(zh)
*
|
2022-01-29 |
2023-08-03 |
江苏恒瑞医药股份有限公司 |
稠杂环类化合物、其制备方法及其在医药上的应用
|
WO2024097606A1
(en)
*
|
2022-10-31 |
2024-05-10 |
Eli Lilly And Company |
Ahr agonists
|